![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
One of our McKesson experts discusses the importance of staying informed as 340B changes continue to unfold.
MHS In the News: Transparency in Drug Pricing Can Start with 340B
Key considerations in understanding 340B program results and benefits.
By
Date
July 13, 2021
Read time: less than 1 minute
A lack of transparency across the pharmacy marketplace stems from a number of different factors. Ultimately, it impacts the patient experience and can create confusion.
Heightened transparency across the broader system could help support health systems’ ability to generate savings and revenue to support extending care to the uninsured and underinsured, which is key to extending pharmacy and patient care services.
Andrew Wilson, vice president, 340B Solutions for McKesson, shares three key considerations in understanding 340B program results and benefits. Read more from Drug Topics.
Related Stories
The most downloaded content by health system pharmacy leaders in August 2025.
With available labor resources dwindling and a shrinking pipeline, health systems must find creative solutions for better using the personnel and partnerships they have.
At this year's event, our experts heard from health systems who may be underutilizing available tools and resources in 340B program management.
Click through this interactive experience for a closer look at what you can expect at this year’s HealthTrust University Conference.
Expert insights into prioritizing 340B as a system-wide program in your health system.
Our experts continue shaping industry conversations through regular conference and event engagements, like the HealthTrust University 340B Summit.
The most downloaded content by health system pharmacy leaders in July 2025.
The top three Prescribed Perspectives articles downloaded by health systems in June.
This visual helps illustrate the nuances of each type of bagging in specialty pharmacy and what it may mean for your health system.